NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and AtriCure (NASDAQ:ATRC – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.
Valuation and Earnings
This table compares NeuroOne Medical Technologies and AtriCure”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $12.10 million | 0.49 | -$3.61 million | ($0.95) | -0.69 |
| AtriCure | $534.53 million | 5.28 | -$11.45 million | $0.30 | 184.63 |
Risk & Volatility
NeuroOne Medical Technologies has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for NeuroOne Medical Technologies and AtriCure, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
| AtriCure | 1 | 4 | 6 | 1 | 2.58 |
NeuroOne Medical Technologies presently has a consensus target price of $7.33, suggesting a potential upside of 1,024.57%. AtriCure has a consensus target price of $62.30, suggesting a potential upside of 12.48%. Given NeuroOne Medical Technologies’ higher possible upside, equities analysts plainly believe NeuroOne Medical Technologies is more favorable than AtriCure.
Profitability
This table compares NeuroOne Medical Technologies and AtriCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -71.50% | -128.12% | -86.34% |
| AtriCure | 2.52% | 4.01% | 3.03% |
Institutional & Insider Ownership
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
AtriCure beats NeuroOne Medical Technologies on 12 of the 15 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies develops medical devices that use thin-film electrode technology for diagnosing and treating neurological disorders. Its products are designed for use by clinicians in procedures involving the brain and nervous system. The company’s portfolio includes Evo cortical and stereoelectroencephalography (sEEG) electrodes, which are used to record brain activity, and the OneRF system, designed to deliver radiofrequency ablation and stimulation. These technologies are intended to support applications including epilepsy diagnosis and treatment.
About AtriCure
AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
